Responses
Clinical trials and drug discovery
Original research
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
Compose a Response to This Article
Other responses
No responses have been published for this article.